New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
Biogen’s (BIIB) Pipelines Offers Multiple Potential Catalysts
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following Childbirth
Is Alzheimer’s Data Altering The Investment Case For Biogen (BIIB)?
Guggenheim Maintains Buy on Biogen, Raises Price Target to $300
HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272
Argus Research Upgrades Biogen to Buy, Announces $280 Price Target
Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272
Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238
UBS Maintains Buy on Biogen, Raises Price Target to $300
TD Cowen Maintains Buy on Biogen, Raises Price Target to $260
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Wedbush Maintains Neutral on Biogen, Raises Price Target to $225
Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.